Eliquis Lawsuits Allege Defective Drug Status
In three separate lawsuits, plaintiffs are alleging anticoagulant Eliquis (also known as apixaban and ARISTOTLE) was rushed to the market without an effective antidote, making it unnecessarily dangerous and defective. If your Coumadin (warfarin) prescription blood thinner was replaced by Eliquis, the St. Louis defective drug attorneys at Hoffman & Gelfman want to make you aware of this potentially deadly drug.
Clinical Trials, Conducted in China, Sadly Lacking
According to plaintiffs the drug makers misrepresented the drug’s risks, and hid knowledge of treatment shortcomings, pointing to “incompetent and untrustworthy” trials in which side effects were withheld from the FDA’s approving body. Poor quality control, lack of available participants for follow-ups, dispensing errors, falsified records, and an unreported (study) death were also alleged.
Lack of Effective Reversing Agent Endangers Patients
Unlike Coumadin, which has an effective reversing agent in-place, plaintiffs also allege Eliquis manufacturers Bristol-Myers Squibb and Pfizer did not disclose the product’s lack of reversing agent on the label, yet marketed the drug aggressively with direct-to-consumer advertisements overstating its efficacy in the prevention of stroke and systemic embolism. Manufacturers also likewise failed to note the potential for life-threatening and fatal consequences due to irreversibility in its campaign.
Concerned about possible complications with your Eliquis prescription? The St. Louis defective drug attorneys at Hoffman & Gelfman can help you seek the compensation you deserve for your injuries. Contact us today.